Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
mahjong games
Popular Articles

PhRMA's Tally: $40 Million To Lobby On Health Care
NPR reports on one of the most powerful players in health care: the Pharmaceutical Research and Manufacturers of America, or PhRMA. In addition to spending $40 million, PhRMA alone has 29 people lobbying for it and has "hired 45 different Washington, D.C., lobbying firms to represent it in those three months of the second quarter."

AACAP Applauds AMA's Support For Universal Vaccinations
The American Academy of Child and Adolescent Psychiatry (AACAP) applauds the American Medical Association (AMA) for reaffirming its policy in support for universal vaccination.
News of the day
NEJM Examines Several Health Issues In Perspective Pieces
The New England Journal of Medicine published a series of perspectives that examine a variety of topics--from the struggle to finance health care reform to vaccine issues, the Food and Drug Administration and prescription drug marketing legislation in Vermont. The collection of perspectives includes a piece by Jonathan Gruber, PhD., "A Win-Win Approach to Financing Health Care Reform" and John K. Iglehart"s examination of Democrat"s challenge to securing money in "Finding Money for Health Care Reform - Rooting Out Waste, Fraud, and Abuse." Another piece, this one by Robert Steinbrook, M.D., examines new legislation in Vermont amid the background of reform of physician-industry relations in his piece "A Higher Bar - Vermont"s New Law on Marketing Prescribed Products."
Medical Devices

UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed No Clinically Relevant Benefit For Patients

UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis showed that patients enrolled in this clinical trial did not benefit as expected from CDP323 compared to placebo after a six month treatment period. No cases of PML (progressive multifocal leukoencephalopathy) were noted. CDP323 is an oral small molecule alpha4 integrin inhibitor that was being developed by UCB and Biogen Idec for relapsing forms of multiple sclerosis. For UCB, results of this interim analysis trigger a re-valuation of the intangible asset "CDP323". UCB expects a non-cash, non-recurring impairment of a high double-digit million pre-tax euro amount. This will be more than compensated by cash, non-recurring capital gains, which resulted from the divestitures UCB made earlier this year. More information on the financial impacts of both the impairment and the capital gains will be included in the Half Year Report 2009 of UCB, due July 31, 2009. About Multiple Sclerosis Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects an estimated 1.1 - 2.5 million people worldwide. Although the exact cause is unknown, MS occurs as a result of loss of the protective outer coating on nerves in the brain and spinal cord. Deterioration in the way that messages are transmitted around the body leads to loss of movement and other body functions. Symptoms of MS can include vision problems, loss of balance, numbness, difficulty walking and paralysis. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009